JCR Pharmaceuticals Co., Ltd. 4552

MILAN & HYOGO, Japan, October 02, 2026--Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.

HYOGO, Japan, September 28, 2026--The Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of DMD.

TOKYO & HYOGO, Japan, September 11, 2026--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.

Moby summary of Acumen Pharmaceuticals, Inc.'s Q2 2026 earnings call

HYOGO, Japan, July 21, 2026--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacyEBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regionsNo hematological safety signals observed in non-human primates, demonstrating low potential

HYOGO, Japan, June 17, 2026--Acumen exercised its option to develop, manufacture, & commercialize, on a global basis, up to two candidates for development in the treatment of AD.

Japan's regenerative medicine market offers opportunities driven by an aging population, progressive regulations, and demand for novel therapies targeting chronic and cosmetic conditions. Innovations in stem cell and gene-editing technologies, alongside robust R&D investments and clinical collaborations, further bolster growth potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Japan Regenerative Medicine Market - Distribution by Type of Product, Type of Therapeutic Area, End User and Key Ge

Moby summary of Acumen Pharmaceuticals, Inc.'s Q4 2025 earnings call

Acumen Pharmaceuticals (NASDAQ:ABOS) executives outlined key clinical and research milestones for the company’s Alzheimer’s disease pipeline during a discussion focused on its lead antibody, sabirnetug, and an enhanced brain delivery (EBD) collaboration with Japan-based JCR Pharmaceuticals. Company